OTCMBRAXF
Market cap453kUSD
Dec 24, Last price
0.00USD
1D
6.67%
1Q
-11.11%
IPO
-99.33%
Name
Braxia Scientific Corp
Chart & Performance
P/E
—
P/S
0.35
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
2m
+26.70%
Net income
-13m
L+8.30%
CFO
-7m
L+63.75%
Earnings
Feb 26, 2025
Profile
Braxia Scientific Corp. operates as a medical research company with clinics that provide ketamine treatments for persons with depression and related disorders. It is also involved in the research activities related to discovering and commercializing novel drugs and delivery methods; and developing ketamine and psilocybin derivatives and other psychedelic products from its IP development platform. In addition, the company owns and operates multidisciplinary clinics for the treatment of mental health disorders. Braxia Scientific Corp. is headquartered in Mississauga, Ontario.
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY |
|---|---|---|---|---|
| 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | |
| Income | ||||
Revenues | 1,884 26.70% | 1,487 47.48% | ||
Cost of revenue | 7,434 | 11,677 | ||
Unusual Expense (Income) | ||||
NOPBT | (5,550) | (10,190) | ||
NOPBT Margin | ||||
Operating Taxes | (146) | (45) | ||
Tax Rate | ||||
NOPAT | (5,404) | (10,145) | ||
Net income | (13,142) 8.30% | (12,134) -86.34% | ||
Dividends | ||||
Dividend yield | ||||
Proceeds from repurchase of equity | 1,264 | 2,715 | ||
BB yield | ||||
| Debt | ||||
Debt current | 76 | 83 | ||
Long-term debt | 233 | 215 | ||
Deferred revenue | ||||
Other long-term liabilities | (1) | |||
Net debt | (1,194) | (8,414) | ||
| Cash flow | ||||
Cash from operating activities | (7,399) | (4,518) | ||
CAPEX | (827) | (25) | ||
Cash from investing activities | (1,128) | (609) | ||
Cash from financing activities | 1,236 | 2,704 | ||
FCF | (6,055) | (10,263) | ||
| Balance | ||||
Cash | 1,462 | 8,678 | ||
Long term investments | 41 | 35 | ||
Excess cash | 1,409 | 8,638 | ||
Stockholders' equity | 1,529 | 8,963 | ||
Invested Capital | 403 | 302 | ||
ROIC | ||||
ROCE | ||||
| EV | ||||
Common stock shares outstanding | 228,421 | 175,244 | ||
Price | ||||
Market cap | ||||
EV | ||||
EBITDA | (4,984) | (10,167) | ||
EV/EBITDA | ||||
Interest | 18 | 5 | ||
Interest/NOPBT | ||||